Transcriptomic Marker Sets for Chlamydial PID Detection and Risk Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively identify women at risk for reproductive organ damage from chlamydial infections, as asymptomatic infections are common and often lead to long-term sequelae such as infertility and ectopic pregnancy, with existing detection methods unable to predict those at elevated risk for these complications.
Innovation Solution
The use of specific marker sets, including TCL1A, HINT3, CDK5RAP3, and others, to detect changes in gene expression levels in biological samples through assays, allowing for the identification of chlamydial pelvic inflammatory disease and the risk of reproductive organ damage, as well as the effectiveness of pharmaceutical agents in treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional detection methods are used for chlamydia infection, then the infection can be detected and treated, but the ability to identify women at risk for reproductive sequelae is lost
Solution Approach 1:
The patent segments the detection approach by dividing the transcriptome into specific marker sets (Table A markers for current infection status, Table B markers for risk prediction). This segmentation allows simultaneous detection of infection and prediction of reproductive sequelae risk through distinct molecular signatures, resolving the contradiction between detection capability and risk information loss.
Solution Approach 2:
The patent adds a new dimension to chlamydia detection by transitioning from single-marker detection to multi-marker transcriptomic profiling. This dimensional expansion enables concurrent assessment of infection status and future risk stratification, transforming a unidimensional detection method into a multidimensional diagnostic tool that preserves both detection accuracy and risk prediction information.
2Ease of operation
If asymptomatic infections are monitored using conventional methods, then treatment can be provided, but long-term reproductive damage risk remains undetected
Solution Approach 1:
The patent changes the parameters of detection by measuring expression levels of multiple transcripts simultaneously rather than relying on single-marker presence/absence. This parameter transformation from binary detection to quantitative multi-parameter profiling enables precise risk stratification while maintaining operational simplicity through standardized assay procedures.
Solution Approach 2:
The patent introduces transcriptomic marker sets as intermediary molecules that mediate between asymptomatic infection detection and risk prediction. These molecular intermediaries (specific transcript expressions) serve as proxies that simultaneously reflect current infection status and future reproductive risk, enabling both functions through a single detection system.
3Measurement precision
If comprehensive transcriptome analysis is performed, then risk prediction accuracy is improved, but assay complexity increases
Solution Approach 1:
The patent extracts only the most informative transcripts from the comprehensive transcriptome, creating focused marker sets (Tables A and B) that contain the essential risk prediction information. This extraction process removes unnecessary complexity by selecting a subset of high-value markers rather than analyzing the entire transcriptome, achieving accurate risk prediction with reduced assay complexity.
Solution Approach 2:
The patent applies partial action by measuring a specific subset of transcripts (46 markers in Table A, 33 markers in Table B) rather than performing exhaustive transcriptome analysis. This partial measurement approach provides sufficient risk prediction accuracy for clinical decision-making while significantly reducing assay complexity, cost, and time requirements compared to complete transcriptome sequencing.
Data Source
AI summary
Methods are provided herein for determining the likelihood that a subject, such as an asymptomatic subject, has chlamydial pelvic inflammatory disease. In some embodiments, the method can determine the likelihood that a pharmaceutical agent is effective for treating a subject that has chlamydial pelvic inflammatory disease. In other specific non-limiting examples, the method predicts endometritis and elevated pathogen burden. The subject is a female, such as a human female.